583 related articles for article (PubMed ID: 33731985)
21. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
23. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
24. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
25. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
26. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
28. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
29. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Sun C; Su Z; Zeng YP
Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
[TBL] [Abstract][Full Text] [Related]
30. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
31. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of new systemic therapies in moderate-to-severe atopic dermatitis in the elderly: meta-analysis].
Wang SS; Pan XY; Li YN; Li W
Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(32):2509-2515. PubMed ID: 37650197
[No Abstract] [Full Text] [Related]
33. Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Soto E; Banfield C; Gupta P; Peterson MC
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):553-560. PubMed ID: 32830463
[TBL] [Abstract][Full Text] [Related]
34. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
35. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H
Immunotherapy; 2022 Jan; 14(1):5-14. PubMed ID: 34775830
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
[TBL] [Abstract][Full Text] [Related]
37. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Chang PH; Huang SF; Chang PS; Yu Y
J Dermatol; 2021 Nov; 48(11):1631-1639. PubMed ID: 34462967
[TBL] [Abstract][Full Text] [Related]
38. Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor.
Bowman CJ; Campion SN; Catlin NR; Nowland WS; Stethem CM; Radi ZA; Cappon GD
Birth Defects Res; 2024 May; 116(5):e2345. PubMed ID: 38716582
[TBL] [Abstract][Full Text] [Related]
39. Abrocitinib for the treatment of atopic dermatitis.
Lé AM; Gooderham M; Torres T
Immunotherapy; 2023 Nov; 15(16):1351-1362. PubMed ID: 37667972
[TBL] [Abstract][Full Text] [Related]
40. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
Drugs Context; 2020; 9():. PubMed ID: 33240390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]